News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies Technologies Reports Full Year 2013 Financial Results And Provides VIPES Update


3/17/2014 9:06:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BAGNEUX, France, March 17, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of ViaskinĀ®, a new standard in the treatment of allergy, announced today its full year 2013 results, approved by the Board of Directors on March 14, 2013. DBV also provided an update on 'VIPES' phase IIb clinical study of ViaskinĀ® Peanut and precised the date on which it will hold an R&D day for the investment community.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES